Center for Vulvovaginal Disorders
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Center for Vulvovaginal Disorders sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Center for Vulvovaginal Disorders: 6 sponsored US clinical trials, 2 recruiting.
Center for Vulvovaginal Disorders sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Provoked Vestibulodynia, with 2 trials.
Upper-quartile sponsor footprint
Center for Vulvovaginal Disorders sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction
NCT07486830
Topical Ketotifen 0.25% for Secondary Vestibulodynia
NCT07257029
StrataMGT for the Treatment of Vulvar Lichen Sclerosus
NCT06360705
MonaLisa Touch Laser for the Treatment of Vulvar Lichen Sclerosus
NCT03665584
Platelet Rich Plasma (PRP) for Vulvar Lichen Sclerosus
NCT03045172
Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus
NCT00393263
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
What is open in the Center for Vulvovaginal Disorders pipeline
2 recruiting of 6 indexed (33% open); 4 completed (67%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Provoked Vestibulodynia (2 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Center for Vulvovaginal Disorders: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Center for Vulvovaginal Disorders sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Center for Vulvovaginal Disorders page
6 registered trials is a research-attention snapshot, not an endorsement of Center for Vulvovaginal Disorders or any single study.
- 2 of Center for Vulvovaginal Disorders's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Provoked Vestibulodynia is the condition Center for Vulvovaginal Disorders studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Provoked Vestibulodynia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Center for Vulvovaginal Disorders pipeline card: 6 registered trials from official public datasets.Report a data error.